Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Link to relevant study record(s)

Description of key information

There are no study data available for the toxicokinetic of the test substance Vulcuren.

Key value for chemical safety assessment

Bioaccumulation potential:
no bioaccumulation potential

Additional information

There are no study data available for the toxicokinetic of the test substance Vulcuren.

The test substance Vulcuren has a solid state under normal condition. The calculated vapor pressure is about 3.9E-20 hPa (25°C) and thus an exposure to the inhalation route could be practically excluded.

The physical and chemical properties (like water solubility < 0.05 mg/l at 25°C, log Pow: 10.4 at 20°C) as well as the molecule size (mol weight: 693.12) let to the conclusion that the oral and dermal resorption rate is low.

This assumption is in line by the available data from acute oral and acute dermal studies (Hüls AG 1992a, Hüls AG 1992b). After a single oral or dermal application of the test substance (2000 mg/kg bw) to male or female rats only transient and weak clinical symptoms and no mortality were seen. On the other hand, no mortality was observed in the in vivo micronucleus assay with male rats, which were treated ip. with up to 4000 mg/kg test substance (twice, 24 h interval) (Bayer 2000c). The bypass of the absorption barrier of the gastrointestinal tract or the skin and thus a presumably higher systemic availability from the test substance, no mortality was seen. This could be evidence that the test substance has a very low intrinsic toxic potential.

In a subacute toxicity study with Wistar rats (Bayer AG 2000f), which were treated per gavage with 0, 40, 200 and 1000 mg/kg bw and day, no substance-related toxicity was observed. Thus, even with a log Pow of 10.4 there is no evidence of appreciable cumulative potential of the test substance. Based on data from the clinical chemistry, gross pathology and histopathology, as well as the evaluation of the excrements, no conclusion of the main elimination ways could be drawn.

The results from the in vitro chromosome aberration assay (Bayer 2000b) showed an increase in cytotoxicity in presence of metabolic activation (S9-mix). Thus, it could be concluded, that the test substance Vulcuren could be metabolized by microsome enzymes of the rat liver; whereas the metabolite is more reactive than Vulcuren. The weak positive effect in the in vitro chromosome aberration assay indicated the induction of DNA-reactive metabolites. However the negative results in the in vivo micronucleus assay (Bayer AG 2000e) and in vivo comet assay (Lanxess GmbH 2005) indicated that in mammalians no appreciable amounts of these DNA-reactive metabolites are generated.